The estimated Net Worth of Viii Lp Canaan Partners Vii... is at least $39.3 millió dollars as of 26 July 2021. Viii Vii owns over 11,375 units of Liquidia Corp stock worth over $26,430,427 and over the last 10 years Viii sold LQDA stock worth over $12,885,261.
Viii has made over 51 trades of the Liquidia Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Viii sold 11,375 units of LQDA stock worth $46,524 on 26 July 2021.
The largest trade Viii's ever made was buying 727,273 units of Liquidia Corp stock on 30 July 2018 worth over $8,000,003. On average, Viii trades about 42,239 units every 41 days since 2014. As of 26 July 2021 Viii still owns at least 2,603,983 units of Liquidia Corp stock.
You can see the complete history of Viii Vii stock trades at the bottom of the page.
Viii's mailing address filed with the SEC is 285 RIVERSIDE AVENUE,285 RIVERSIDE AVENUE,, SUITE 250SUITE 250, WESTPORTWESTPORT, CTCT, 0688006880.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: